Could CD47 Competitors Catch Up To Gilead After Magrolimab Hold?

Cancer cells on scientific background.3d illustration
Gilead said the FDA had placed a partial hold on its trials testing magrolimab with Vidaza • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D